The future of a $4-billion-a-year Eli Lilly and Co. drug is at stake as a federal judge weighs whether the company should continue to hold its Zyprexa patent in the face of a challenge from makers of generic drugs.
The future of a $4-billion-a-year Eli Lilly and Co. drug is at stake as a federal judge weighs whether the company should continue to hold its Zyprexa patent in the face of a challenge from makers of generic drugs.
